253 related articles for article (PubMed ID: 11897598)
1. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Saiman L; Chen Y; Gabriel PS; Knirsch C
Antimicrob Agents Chemother; 2002 Apr; 46(4):1105-7. PubMed ID: 11897598
[TBL] [Abstract][Full Text] [Related]
2. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.
Saiman L; Tabibi S; Starner TD; San Gabriel P; Winokur PL; Jia HP; McCray PB; Tack BF
Antimicrob Agents Chemother; 2001 Oct; 45(10):2838-44. PubMed ID: 11557478
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
Mathy V; Grohs P; Compain F
J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
Zhang L; Li XZ; Poole K
J Antimicrob Chemother; 2001 Oct; 48(4):549-52. PubMed ID: 11581236
[TBL] [Abstract][Full Text] [Related]
5. Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
Farfour E; Trochu E; Devin C; Cardot Martin E; Limousin L; Roux A; Picard C; Jolly E; Vasse M; Lesprit P
Transpl Infect Dis; 2018 Oct; 20(5):e12955. PubMed ID: 29896802
[No Abstract] [Full Text] [Related]
6. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
Traczewski MM; Brown SD
Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
[TBL] [Abstract][Full Text] [Related]
7. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Saiman L; Chen Y; Tabibi S; San Gabriel P; Zhou J; Liu Z; Lai L; Whittier S
J Clin Microbiol; 2001 Nov; 39(11):3942-5. PubMed ID: 11682511
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.
Vu-Thien H; Moissenet D; Valcin M; Dulot C; Tournier G; Garbarg-Chenon A
Eur J Clin Microbiol Infect Dis; 1996 Nov; 15(11):876-9. PubMed ID: 8997562
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of antimicrobials against
Spierer O; Miller D; O'Brien TP
Br J Ophthalmol; 2018 May; 102(5):708-712. PubMed ID: 29459431
[TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
Ratjen A; Yau Y; Wettlaufer J; Matukas L; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V
Antimicrob Agents Chemother; 2015 Jan; 59(1):711-3. PubMed ID: 25348526
[TBL] [Abstract][Full Text] [Related]
12. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
Lobo LJ; Tulu Z; Aris RM; Noone PG
Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
[TBL] [Abstract][Full Text] [Related]
13.
Caverly LJ; Spilker T; Kalikin LM; Stillwell T; Young C; Huang DB; LiPuma JJ
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611364
[TBL] [Abstract][Full Text] [Related]
14. Emerging microorganisms in cystic fibrosis.
Fabbri A; Tacchella A; Manno G; Viscoli C; Palmero C; Gargani GF
Chemioterapia; 1987 Feb; 6(1):32-7. PubMed ID: 3103930
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
Conway SP; Brownlee KG; Denton M; Peckham DG
Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
[TBL] [Abstract][Full Text] [Related]
16. Microbiology of airway disease in a cohort of patients with cystic fibrosis.
Lambiase A; Raia V; Del Pezzo M; Sepe A; Carnovale V; Rossano F
BMC Infect Dis; 2006 Jan; 6():4. PubMed ID: 16405721
[TBL] [Abstract][Full Text] [Related]
17. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Nazik H; Ongen B; Erturan Z; Salcioğlu M
Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis.
Kurlandsky LE; Fader RC
Pediatr Pulmonol; 2000 Mar; 29(3):210-2. PubMed ID: 10686042
[TBL] [Abstract][Full Text] [Related]
19. The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains.
Alkawash M; Head M; Alshami I; Soothill JS
J Antimicrob Chemother; 1999 Sep; 44(3):385-7. PubMed ID: 10511407
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.
San Gabriel P; Zhou J; Tabibi S; Chen Y; Trauzzi M; Saiman L
Antimicrob Agents Chemother; 2004 Jan; 48(1):168-71. PubMed ID: 14693535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
